Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies

Bahram Forouzesh, Manuel Hidalgo, Quincy Chu, Alain Mita, Monica Mita, Garry Schwartz, José Jimeno, Javier Gómez, Vicente Alfaro, Claudia Lebedinsky, Patrik Zintl, Eric K. Rowinsky

Research output: Contribution to journalArticle

Abstract

Purpose: This study was designed to determine the safety, tolerability, and pharmacokinetics, and to seek preliminary evidence of anticancer activity of trabectedin, a novel marine-derived DNA minor grove binder, when administered as a 1-hour or 3-hour i.v. infusion for 3 consecutive weeks every 4 weeks in patients with advanced solid malignancies. The study also sought to determine the maximum tolerated dose (MTD) levels of trabectedin on these schedules, as well as to recommend doses for disease-directed studies. Experimental Design: A total of 32 and 31 patients were treated in sequential cohorts with trabectedin on the 1-hour schedule (doses ranging from 0.46 to 0.80 mg/m2) and on the 3-hour schedule (doses ranging from 0.30 to 0.65 mg/m2). Results: Neutropenia, transient elevations in hepatic transaminases and creatine phosphokinase, and fatigue precluded dose escalation above 0.70 mg/m2 (1-hour schedule) and 0.65 mg/m2 (3-hour schedule), which were determined to be the MTD levels, respectively. The pharmacokinetics of trabectedin on both schedules were characterized by a high clearance rate, a long terminal half-life, and a large volume of distribution. A patient with soft tissue sarcoma had partial response, and several soft tissue sarcoma patients had prolonged (≥6 months) stable disease. Conclusions: The MTD levels of trabectedin given weekly for 3 weeks every 4 weeks is 0.61 mg/m2 as a 1-hour infusion and 0.58 mg/m2 as a 3-hour infusion. The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.

Original languageEnglish (US)
Pages (from-to)3591-3599
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number10
DOIs
StatePublished - May 15 2009
Externally publishedYes

Fingerprint

trabectedin
Appointments and Schedules
Pharmacokinetics
Maximum Tolerated Dose
Neoplasms
Sarcoma
Creatine Kinase
Transaminases
Neutropenia
Fatigue
Half-Life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. / Forouzesh, Bahram; Hidalgo, Manuel; Chu, Quincy; Mita, Alain; Mita, Monica; Schwartz, Garry; Jimeno, José; Gómez, Javier; Alfaro, Vicente; Lebedinsky, Claudia; Zintl, Patrik; Rowinsky, Eric K.

In: Clinical Cancer Research, Vol. 15, No. 10, 15.05.2009, p. 3591-3599.

Research output: Contribution to journalArticle

Forouzesh, B, Hidalgo, M, Chu, Q, Mita, A, Mita, M, Schwartz, G, Jimeno, J, Gómez, J, Alfaro, V, Lebedinsky, C, Zintl, P & Rowinsky, EK 2009, 'Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies', Clinical Cancer Research, vol. 15, no. 10, pp. 3591-3599. https://doi.org/10.1158/1078-0432.CCR-08-2889
Forouzesh, Bahram ; Hidalgo, Manuel ; Chu, Quincy ; Mita, Alain ; Mita, Monica ; Schwartz, Garry ; Jimeno, José ; Gómez, Javier ; Alfaro, Vicente ; Lebedinsky, Claudia ; Zintl, Patrik ; Rowinsky, Eric K. / Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 10. pp. 3591-3599.
@article{00a9b170940646d9b7c92ccf7bd90932,
title = "Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies",
abstract = "Purpose: This study was designed to determine the safety, tolerability, and pharmacokinetics, and to seek preliminary evidence of anticancer activity of trabectedin, a novel marine-derived DNA minor grove binder, when administered as a 1-hour or 3-hour i.v. infusion for 3 consecutive weeks every 4 weeks in patients with advanced solid malignancies. The study also sought to determine the maximum tolerated dose (MTD) levels of trabectedin on these schedules, as well as to recommend doses for disease-directed studies. Experimental Design: A total of 32 and 31 patients were treated in sequential cohorts with trabectedin on the 1-hour schedule (doses ranging from 0.46 to 0.80 mg/m2) and on the 3-hour schedule (doses ranging from 0.30 to 0.65 mg/m2). Results: Neutropenia, transient elevations in hepatic transaminases and creatine phosphokinase, and fatigue precluded dose escalation above 0.70 mg/m2 (1-hour schedule) and 0.65 mg/m2 (3-hour schedule), which were determined to be the MTD levels, respectively. The pharmacokinetics of trabectedin on both schedules were characterized by a high clearance rate, a long terminal half-life, and a large volume of distribution. A patient with soft tissue sarcoma had partial response, and several soft tissue sarcoma patients had prolonged (≥6 months) stable disease. Conclusions: The MTD levels of trabectedin given weekly for 3 weeks every 4 weeks is 0.61 mg/m2 as a 1-hour infusion and 0.58 mg/m2 as a 3-hour infusion. The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.",
author = "Bahram Forouzesh and Manuel Hidalgo and Quincy Chu and Alain Mita and Monica Mita and Garry Schwartz and Jos{\'e} Jimeno and Javier G{\'o}mez and Vicente Alfaro and Claudia Lebedinsky and Patrik Zintl and Rowinsky, {Eric K.}",
year = "2009",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-08-2889",
language = "English (US)",
volume = "15",
pages = "3591--3599",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies

AU - Forouzesh, Bahram

AU - Hidalgo, Manuel

AU - Chu, Quincy

AU - Mita, Alain

AU - Mita, Monica

AU - Schwartz, Garry

AU - Jimeno, José

AU - Gómez, Javier

AU - Alfaro, Vicente

AU - Lebedinsky, Claudia

AU - Zintl, Patrik

AU - Rowinsky, Eric K.

PY - 2009/5/15

Y1 - 2009/5/15

N2 - Purpose: This study was designed to determine the safety, tolerability, and pharmacokinetics, and to seek preliminary evidence of anticancer activity of trabectedin, a novel marine-derived DNA minor grove binder, when administered as a 1-hour or 3-hour i.v. infusion for 3 consecutive weeks every 4 weeks in patients with advanced solid malignancies. The study also sought to determine the maximum tolerated dose (MTD) levels of trabectedin on these schedules, as well as to recommend doses for disease-directed studies. Experimental Design: A total of 32 and 31 patients were treated in sequential cohorts with trabectedin on the 1-hour schedule (doses ranging from 0.46 to 0.80 mg/m2) and on the 3-hour schedule (doses ranging from 0.30 to 0.65 mg/m2). Results: Neutropenia, transient elevations in hepatic transaminases and creatine phosphokinase, and fatigue precluded dose escalation above 0.70 mg/m2 (1-hour schedule) and 0.65 mg/m2 (3-hour schedule), which were determined to be the MTD levels, respectively. The pharmacokinetics of trabectedin on both schedules were characterized by a high clearance rate, a long terminal half-life, and a large volume of distribution. A patient with soft tissue sarcoma had partial response, and several soft tissue sarcoma patients had prolonged (≥6 months) stable disease. Conclusions: The MTD levels of trabectedin given weekly for 3 weeks every 4 weeks is 0.61 mg/m2 as a 1-hour infusion and 0.58 mg/m2 as a 3-hour infusion. The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.

AB - Purpose: This study was designed to determine the safety, tolerability, and pharmacokinetics, and to seek preliminary evidence of anticancer activity of trabectedin, a novel marine-derived DNA minor grove binder, when administered as a 1-hour or 3-hour i.v. infusion for 3 consecutive weeks every 4 weeks in patients with advanced solid malignancies. The study also sought to determine the maximum tolerated dose (MTD) levels of trabectedin on these schedules, as well as to recommend doses for disease-directed studies. Experimental Design: A total of 32 and 31 patients were treated in sequential cohorts with trabectedin on the 1-hour schedule (doses ranging from 0.46 to 0.80 mg/m2) and on the 3-hour schedule (doses ranging from 0.30 to 0.65 mg/m2). Results: Neutropenia, transient elevations in hepatic transaminases and creatine phosphokinase, and fatigue precluded dose escalation above 0.70 mg/m2 (1-hour schedule) and 0.65 mg/m2 (3-hour schedule), which were determined to be the MTD levels, respectively. The pharmacokinetics of trabectedin on both schedules were characterized by a high clearance rate, a long terminal half-life, and a large volume of distribution. A patient with soft tissue sarcoma had partial response, and several soft tissue sarcoma patients had prolonged (≥6 months) stable disease. Conclusions: The MTD levels of trabectedin given weekly for 3 weeks every 4 weeks is 0.61 mg/m2 as a 1-hour infusion and 0.58 mg/m2 as a 3-hour infusion. The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.

UR - http://www.scopus.com/inward/record.url?scp=66149170084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149170084&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2889

DO - 10.1158/1078-0432.CCR-08-2889

M3 - Article

C2 - 19417019

AN - SCOPUS:66149170084

VL - 15

SP - 3591

EP - 3599

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -